LongDFTXJun 2026
Definium Therapeutics, Inc.
Meridian owns Definium Therapeutics for what it sees as a potentially best-in-class rapid-acting, single-dose therapy profile in large underserved mental-health markets. Positive…
DFTX
1 published idea on Definium Therapeutics, Inc. across 1 fund — 1 long and 0 short.
Each entry below comes from a hedge fund's own investor letter, not a 13F filing, so it carries the reasoning behind the position on Definium Therapeutics, Inc.: the full thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Meridian owns Definium Therapeutics for what it sees as a potentially best-in-class rapid-acting, single-dose therapy profile in large underserved mental-health markets. Positive…